Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250640 | 0.91 | HTR1A (0.53) | HTR1AHTR2ATMEM97THRBPER2 | |
| SCHEMBL5242210 | 0.86 | HTR1A (0.43) | HTR1AHTR2ATMEM97GRM5THRB | |
| SCHEMBL2029501 | 0.86 | HTR1A (0.43) | HTR1AHTR2ATMEM97GRM5THRB | |
| SCHEMBL2023076 | 0.84 | GPR119 (0.48) | HTR1AHTR2ATMEM97 | |
| SCHEMBL5240742 | 0.83 | ADAM17 (0.45) | HTR1AHTR2ATMEM97THRBADAM17 | |
| SCHEMBL5240763 | 0.83 | GRM5 (0.48) | HTR1AHTR2ATMEM97GRM5PARP1 | |
| SCHEMBL5250167 | 0.83 | HTR1A (0.60) | HTR1AHTR2ATMEM97GRM5PARP1 | |
| SCHEMBL5254146 | 0.81 | HTR2A (0.81) | HTR1AHTR2ATMEM97 | |
| Hydrochloric Acid SCHEMBL5248496 | 0.80 | HTR2A (0.79) | HTR1AHTR2ATMEM97 | |
| SCHEMBL2028047 | 0.80 | PARP1 (0.48) | HTR1AHTR2ATMEM97GRM5PER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | claimed |
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 79/4885HTR2A 153/4885TMEM97 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.